Brownstone Institute
How Long Is the Road to Recovery?
From the Brownstone Institute
It should be evident to all now that Covid vaccines do not reduce transmission, that children have a truly minuscule risk from the disease and that their risk from serious adverse effects from vaccination is far to high to justify the inoculations.
Some countries, for example Denmark, have even banned the Covid vaccines for children under 18.
Today I saw a new poll from the US on attitudes towards vaccination and how worried people are about Covid-19. According to the poll an astounding 22 percent of parents are very worried their child will become seriously ill with Covid-19, and another 25 percent are somewhat worried, 47 percent in all. And 42 percent of parents of 12-17 year-old children either have or plan to inject them with the so-called “bivalent booster” (yes, the one tested on eight mice).
In other words, more than a fifth of American adults believe a disease with an infection fatality rate that is probably around one in half a million for children and a truly minuscule hospitalisation rate, is very likely to severely harm their child.
In a radio interview recently I was asked why I thought the reaction to the coronavirus had been so extreme. I said my best guess was mass panic as per Mattias Desmet’s hypothesis. Understandably, the reporter then asked how likely it really was that more or less the whole world would succumb to such extreme mass-formation; to her it didn’t sound credible. And it isn’t. I must admit this is a question I keep asking myself also, again and again.
However, in the end my conclusion is always the same: I still don’t have a better explanation, and a poll result such as the one I’m quoting here supports it; there is something seriously wrong when a fifth of the American population believes something as outrageously erroneous as this. As strange as this may seem, what else could explain such utter disconnect from reality?
Mass panic doesn’t happen by itself, however. What triggers it is the massive amount of propaganda, of fear-mongering, of misinformation pumped out by governments, by the media, by the tech giants over the past three years. The propaganda works, there is no doubt about that. Let alone when dissenting voices are silenced also and the official narrative is all people have access to through the mainstream sources.
What grows from propaganda and censorship are wrong beliefs, even mass panic as we have clearly seen from countless examples. Propaganda and censorship are the seeds. But we must not overlook another crucial component. This is the soil itself. And the soil that allows mass-formation to grow from propaganda and censorship is of our own making; it is our own lack of critical thinking. We do not doubt. We do not question. We do not employ and trust our own judgment. We do not make the effort to verify what we’re told, to seek out information by ourselves, for the information is there if we really look for it. This is the reason we have ended up where we are.
We may eventually get out of the Covid panic. But as long as the soil is fertile; as long as we do not question, do not doubt, but blindly believe and obey, the sword of mass panic, and all the damage done by it, still hangs over our heads. We have to rid ourselves of this threat. What is at stake is freedom and democracy.
The road to recovery will be long, and it will be strewn with difficulties. But we have no choice but to start the journey, and our guiding lights must be courage and integrity, and doubt; always doubt. We owe it to ourselves and we owe it to our children.
Reposted from the author’s Substack
Author
From the Brownstone Institute
A walk through a dozen convenience stores in Montgomery County, Pennsylvania, says a lot about how US nicotine policy actually works. Only about one in eight nicotine-pouch products for sale is legal. The rest are unauthorized—but they’re not all the same. Some are brightly branded, with uncertain ingredients, not approved by any Western regulator, and clearly aimed at impulse buyers. Others—like Sweden’s NOAT—are the opposite: muted, well-made, adult-oriented, and already approved for sale in Europe.
Yet in the United States, NOAT has been told to stop selling. In September 2025, the Food and Drug Administration (FDA) issued the company a warning letter for offering nicotine pouches without marketing authorization. That might make sense if the products were dangerous, but they appear to be among the safest on the market: mild flavors, low nicotine levels, and recyclable paper packaging. In Europe, regulators consider them acceptable. In America, they’re banned. The decision looks, at best, strange—and possibly arbitrary.
What the Market Shows
My October 2025 audit was straightforward. I visited twelve stores and recorded every distinct pouch product visible for sale at the counter. If the item matched one of the twenty ZYN products that the FDA authorized in January, it was counted as legal. Everything else was counted as illegal.
Two of the stores told me they had recently received FDA letters and had already removed most illegal stock. The other ten stores were still dominated by unauthorized products—more than 93 percent of what was on display. Across all twelve locations, about 12 percent of products were legal ZYN, and about 88 percent were not.
The illegal share wasn’t uniform. Many of the unauthorized products were clearly high-nicotine imports with flashy names like Loop, Velo, and Zimo. These products may be fine, but some are probably high in contaminants, and a few often with very high nicotine levels. Others were subdued, plainly meant for adult users. NOAT was a good example of that second group: simple packaging, oat-based filler, restrained flavoring, and branding that makes no effort to look “cool.” It’s the kind of product any regulator serious about harm reduction would welcome.
Enforcement Works
To the FDA’s credit, enforcement does make a difference. The two stores that received official letters quickly pulled their illegal stock. That mirrors the agency’s broader efforts this year: new import alerts to detain unauthorized tobacco products at the border (see also Import Alert 98-06), and hundreds of warning letters to retailers, importers, and distributors.
But effective enforcement can’t solve a supply problem. The list of legal nicotine-pouch products is still extremely short—only a narrow range of ZYN items. Adults who want more variety, or stores that want to meet that demand, inevitably turn to gray-market suppliers. The more limited the legal catalog, the more the illegal market thrives.
Why the NOAT Decision Appears Bizarre
The FDA’s own actions make the situation hard to explain. In January 2025, it authorized twenty ZYN products after finding that they contained far fewer harmful chemicals than cigarettes and could help adult smokers switch. That was progress. But nine months later, the FDA has approved nothing else—while sending a warning letter to NOAT, arguably the least youth-oriented pouch line in the world.
The outcome is bad for legal sellers and public health. ZYN is legal; a handful of clearly risky, high-nicotine imports continue to circulate; and a mild, adult-market brand that meets European safety and labeling rules is banned. Officially, NOAT’s problem is procedural—it lacks a marketing order. But in practical terms, the FDA is punishing the very design choices it claims to value: simplicity, low appeal to minors, and clean ingredients.
This approach also ignores the differences in actual risk. Studies consistently show that nicotine pouches have far fewer toxins than cigarettes and far less variability than many vapes. The biggest pouch concerns are uneven nicotine levels and occasional traces of tobacco-specific nitrosamines, depending on manufacturing quality. The serious contamination issues—heavy metals and inconsistent dosage—belong mostly to disposable vapes, particularly the flood of unregulated imports from China. Treating all “unauthorized” products as equally bad blurs those distinctions and undermines proportional enforcement.
A Better Balance: Enforce Upstream, Widen the Legal Path
My small Montgomery County survey suggests a simple formula for improvement.
First, keep enforcement targeted and focused on suppliers, not just clerks. Warning letters clearly change behavior at the store level, but the biggest impact will come from auditing distributors and importers, and stopping bad shipments before they reach retail shelves.
Second, make compliance easy. A single-page list of authorized nicotine-pouch products—currently the twenty approved ZYN items—should be posted in every store and attached to distributor invoices. Point-of-sale systems can block barcodes for anything not on the list, and retailers could affirm, once a year, that they stock only approved items.
Third, widen the legal lane. The FDA launched a pilot program in September 2025 to speed review of new pouch applications. That program should spell out exactly what evidence is needed—chemical data, toxicology, nicotine release rates, and behavioral studies—and make timely decisions. If products like NOAT meet those standards, they should be authorized quickly. Legal competition among adult-oriented brands will crowd out the sketchy imports far faster than enforcement alone.
The Bottom Line
Enforcement matters, and the data show it works—where it happens. But the legal market is too narrow to protect consumers or encourage innovation. The current regime leaves a few ZYN products as lonely legal islands in a sea of gray-market pouches that range from sensible to reckless.
The FDA’s treatment of NOAT stands out as a case study in inconsistency: a quiet, adult-focused brand approved in Europe yet effectively banned in the US, while flashier and riskier options continue to slip through. That’s not a public-health victory; it’s a missed opportunity.
If the goal is to help adult smokers move to lower-risk products while keeping youth use low, the path forward is clear: enforce smartly, make compliance easy, and give good products a fair shot. Right now, we’re doing the first part well—but failing at the second and third. It’s time to fix that.
Author
From the Brownstone Institute
Cigarettes kill nearly half a million Americans each year. Everyone knows it, including the Food and Drug Administration. Yet while the most lethal nicotine product remains on sale in every gas station, the FDA continues to block or delay far safer alternatives.
Nicotine pouches—small, smokeless packets tucked under the lip—deliver nicotine without burning tobacco. They eliminate the tar, carbon monoxide, and carcinogens that make cigarettes so deadly. The logic of harm reduction couldn’t be clearer: if smokers can get nicotine without smoke, millions of lives could be saved.
Sweden has already proven the point. Through widespread use of snus and nicotine pouches, the country has cut daily smoking to about 5 percent, the lowest rate in Europe. Lung-cancer deaths are less than half the continental average. This “Swedish Experience” shows that when adults are given safer options, they switch voluntarily—no prohibition required.
In the United States, however, the FDA’s tobacco division has turned this logic on its head. Since Congress gave it sweeping authority in 2009, the agency has demanded that every new product undergo a Premarket Tobacco Product Application, or PMTA, proving it is “appropriate for the protection of public health.” That sounds reasonable until you see how the process works.
Manufacturers must spend millions on speculative modeling about how their products might affect every segment of society—smokers, nonsmokers, youth, and future generations—before they can even reach the market. Unsurprisingly, almost all PMTAs have been denied or shelved. Reduced-risk products sit in limbo while Marlboros and Newports remain untouched.
Only this January did the agency relent slightly, authorizing 20 ZYN nicotine-pouch products made by Swedish Match, now owned by Philip Morris. The FDA admitted the obvious: “The data show that these specific products are appropriate for the protection of public health.” The toxic-chemical levels were far lower than in cigarettes, and adult smokers were more likely to switch than teens were to start.
The decision should have been a turning point. Instead, it exposed the double standard. Other pouch makers—especially smaller firms from Sweden and the US, such as NOAT—remain locked out of the legal market even when their products meet the same technical standards.
The FDA’s inaction has created a black market dominated by unregulated imports, many from China. According to my own research, roughly 85 percent of pouches now sold in convenience stores are technically illegal.
The agency claims that this heavy-handed approach protects kids. But youth pouch use in the US remains very low—about 1.5 percent of high-school students according to the latest National Youth Tobacco Survey—while nearly 30 million American adults still smoke. Denying safer products to millions of addicted adults because a tiny fraction of teens might experiment is the opposite of public-health logic.
There’s a better path. The FDA should base its decisions on science, not fear. If a product dramatically reduces exposure to harmful chemicals, meets strict packaging and marketing standards, and enforces Tobacco 21 age verification, it should be allowed on the market. Population-level effects can be monitored afterward through real-world data on switching and youth use. That’s how drug and vaccine regulation already works.
Sweden’s evidence shows the results of a pragmatic approach: a near-smoke-free society achieved through consumer choice, not coercion. The FDA’s own approval of ZYN proves that such products can meet its legal standard for protecting public health. The next step is consistency—apply the same rules to everyone.
Combustion, not nicotine, is the killer. Until the FDA acts on that simple truth, it will keep protecting the cigarette industry it was supposed to regulate.
Author
The era of Climate Change Alarmism is over
B.C. government laid groundwork for turning private property into Aboriginal land
Danish Cows Collapsing Under Mandatory Methane-Reducing Additive
A Story So Good Not Even The Elbows Up Crew Could Ruin It
-
Daily Caller1 day agoUS Eating Canada’s Lunch While Liberals Stall – Trump Admin Announces Record-Shattering Energy Report
-
Censorship Industrial Complex2 days agoHow the UK and Canada Are Leading the West’s Descent into Digital Authoritarianism
-
Energy1 day agoEby should put up, shut up, or pay up
-
Business14 hours agoU.S. Supreme Court frosty on Trump’s tariff power as world watches
-
Business2 days agoCapital Flight Signals No Confidence In Carney’s Agenda
-
espionage8 hours agoU.S. Charges Three More Chinese Scholars in Wuhan Bio-Smuggling Case, Citing Pattern of Foreign Exploitation in American Research Labs
-
Business2 days agoFederal budget: Carney government posts largest deficit in Canadian history outside pandemic
-
International2 days agoThe capital of capitalism elects a socialist mayor